drugset / Trial / NCT01649765

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

NCT01649765

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multi-center study to evaluate the safety, pharmacokinetics, and efficacy of belimumab intravenous (IV) in pediatric patients 5 to 17 years of age with active systemic lupus erythematosus

Timeline

Start
2012-09-07
Primary completion
2018-01-24
Completion
2025-09-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Belimumab Monoclonal antibody 10 mg/kg Intravenous